Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study
| Image |  |
|---|---|
| Description | scientific article published on 06 October 2020 |
| Author/s |
author: Stephen D. Silberstein |
| Publication date | October 6, 2020 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |